SPDL1 and non-small cell lung carcinoma: A similar study in NSCLC patients treated with anti-PD-1 or anti-PD-L1 monotherapy found that elevated baseline sPD-L1 correlated with both shorter PFS (median: 76 vs 132 days, p = 0.019, Fig. 2A) and OS (median: 115 vs 444 days, p < 0.001, Fig. 2B) [78].